DTIL on Nasdaq

Precision BioSciences

Logo: precisionbiosciences.com5

American gene editing company

Precision BioSciences, Inc. is a publicly traded American clinical stage gene editing company headquartered in Durham, North Carolina.3 From Wikipedia, CC BY-SA 4.0

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with X4 Pharmaceuticals, Inc, Scholar Rock Holding Corp or C4 Therapeutics (United States), or pick any stock.

  • TickerDTIL on Nasdaq1
  • Industrybiotechnology industry1
  • HeadquartersDurham1
  • Websiteprecisionbiosciences.com
  • Incorporated inDE6
  • Business address302 East Pettigrew Street, Suite A-100, Durham, Nc 277016
  • Filer categoryNon-accelerated filer, Smaller reporting company6
  • Legal formCorporation4
  • LEI549300I5QGRS3BLHZH414
  • StatusActive4
  • LEI statusLapsed (not renewed)4
  • Registered addressC/O THE CORPORATION TRUST COMPANY, 19801 Wilmington, United States4
  • Registered withDivision of Corporations, Department of State, 41003844

See how the biggest companies compare on our leaderboards

Precision BioSciences image from its website
Image: precisionbiosciences.com5

Precision BioSciences, Inc. is a publicly traded American clinical stage gene editing company headquartered in Durham, North Carolina. Founded in 2006, Precision is focused on developing both in vivo and ex vivo gene editing therapies using its proprietary "ARCUS" genome editing platform.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-152.2%Operating margin8
-133.4%Net margin8
-50.1%Revenue growth, 20258
-49.6%Return on equity8

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Research and development100¢$54.2M

Out of $34.3M in revenue.8 The company lost money this year.

Financial statements

Revenue9101112138$34.3M in 2025+54% since 2019
0$50.0M$100.0M$150.0M2019: $22.2M$22.2M20192020: $24.3M$24.3M2020+9%2021: $115.5M$115.5M2021+376%2022: $25.1M$25.1M2022−78%2023: $48.7M$48.7M2023+94%2024: $68.7M$68.7M2024+41%2025: $34.3M$34.3M2025−50%
Operating income9101112138-$52.1M in 2025−40% since 2019
-$150.0M-$100.0M-$50.0M02019: -$87.2M-$87.2M20192020: -$109.8M-$109.8M2020+26%2021: -$39.4M-$39.4M2021−64%2022: -$62.3M-$62.3M2022+58%2023: -$43.7M-$43.7M2023−30%2024: -$26.2M-$26.2M2024−40%2025: -$52.1M-$52.1M2025+99%
Net income9101112138-$45.7M in 2025−51% since 2019
-$150.0M-$100.0M-$50.0M0$50.0M2019: -$92.9M-$92.9M20192020: -$109.0M-$109.0M2020+17%2021: -$30.6M-$30.6M2021−72%2022: -$111.6M-$111.6M2022+265%2023: -$61.3M-$61.3M2023−45%2024: $7.2M$7.2M20242025: -$45.7M-$45.7M2025

Every line of the income statement as filed: the last 2 fiscal years, latest first.8

Period ending2025-12-312024-12-31
Revenue$34.3M$68.7M
Research and development$54.2M$59.6M
General and administrative$32.2M$35.3M
Total operating expenses$86.4M$94.9M
Operating loss-$52.1M-$26.2M
Loss from equity method investment-$5.3M-$1.1M
(Loss) gain on changes in other fair value adjustments-$2.7M$258.0K
Gain on change in fair value of warrant liability$11.1M$29.6M
Interest expense$1.4M$1.8M
Interest income$4.2M$6.8M
Loss on disposal of assets-$421.0K-$436.0K
Impairment charges-$36.0K$0
Total other income$5.5M$33.3M
(Loss) income from continuing operations-$46.6M$7.2M
Gain from discontinued operations$885.0K$0
Net (loss) income-$45.7M$7.2M
Basic (in USD per shares)-$3.56$1.05
Diluted (in USD per shares)-$3.56$1.04
Basic (in shares)12.8M shares6.8M shares
Diluted (in shares)12.8M shares6.9M shares

Compare Precision BioSciences with another company

The story

Derek Jantz and Jeff Smith met as postdoctoral fellows at Duke University, and in March 2006, they founded Precision BioSciences along with Matt Kane, a student at the Duke Fuqua School of Business at the time. The company went through two rounds of early funding: a Series A round led by venBio to fund development of the genome editing platform, and Series B financing to fund product development efforts. The company completed its initial public offering in 2019, and trades under the Nasdaq ticker DTIL.

Precision entered into a partnership with Eli Lilly in November 2020 to use ARCUS editing for up to six in vivo targets connected to genetic disorders, beginning with Duchenne muscular dystrophy. In September 2021, Precision announced two more collaborations, with UK biotechnology company Tiziana Life Sciences to explore using foralumab to aid chimeric antigen receptor (CAR) T cell therapy, and with Philadelphia-based iECURE to advance candidates into clinical trials and investigate how ARCUS can help treat liver diseases. Michael Amoroso, the former CEO of cell and gene therapy developer Abeona Therapeutics, succeeded Matt Kane as President and CEO in October 2021. That December, Precision announced its entry into an agreement with a syndicate of investors led by ACCELR8 to spin off its subsidiary, Elo Life Systems, and create an independent company focused on food and agriculture business.

From Wikipedia’s article on Precision BioSciences, shared under CC BY-SA 4.0.7

Leadership

Who has led Precision BioSciences, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Fayaz Khazi2019–2021
  2. Matthew R. Kane2019–2021
  3. Michael Amoroso2021–now

President

  1. Matthew R. Kane2019–2021
  2. Michael Amoroso2021–now

Chief financial officer

  1. Abid Ansari2019–2020
  2. Naresh Haresh Tanna2026–now

Chief operating officer

  1. David S. Thomson2019–2021
20202025
Board members and other officers (21)

Timeline

  1. Oct 19, 2021New chief executive Michael Amoroso becomes CEO16
  2. Mar 27, 2019New chief executive Fayaz Khazi becomes CEO17
  3. Mar 27, 2019New chief executive Matthew R. Kane becomes CEO18
  4. Jan 26, 2006Founded Precision BioSciences is founded4

Filings

396 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 79 major events, 174 insider forms, 46 large holders, 77 other. The latest 20:

  1. Sep 30, 20264 EDGAR
  2. Sep 29, 20264 EDGAR
  3. Sep 29, 20264 EDGAR
  4. Aug 24, 2026SCHEDULE 13G/A EDGAR
  5. Aug 24, 20268-K EDGAR
  6. Aug 7, 2026S-8 EDGAR
  7. Aug 6, 202610-Q EDGAR
  8. Aug 6, 20268-K EDGAR
  9. Aug 3, 20263 EDGAR
  10. Aug 3, 20263 EDGAR
  11. Aug 3, 20263 EDGAR
  12. Jul 29, 2026SCHEDULE 13G/A EDGAR
  13. Jul 27, 20268-K EDGAR
  14. Jul 20, 2026SCHEDULE 13G EDGAR
  15. Jul 1, 20268-K EDGAR
  16. Jun 16, 20268-K EDGAR
  17. Jun 5, 20264 EDGAR
  18. Jun 5, 20264 EDGAR
  19. Jun 5, 20264 EDGAR
  20. Jun 5, 20264 EDGAR

The 396 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

66 open-market trades by officers, directors and large owners since October 2021: 24 buys and 42 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 28, 2026Frankel StanleyDirectorBuy1,000$6.00$6.0KForm 4
Sep 25, 2026Brown MelindaDirectorBuy1,135$6.27$7.1KForm 4
Sep 25, 2026Germano Geno JDirectorBuy2,609$6.28$16.4KForm 4
Feb 18, 2026Amoroso MichaelPresident and CEOSale20,559$3.84$78.9KForm 4
Feb 18, 2026Kelly John AlexanderChief Financial OfficerSale8,149$3.84$31.3KForm 4
Feb 18, 2026Scimeca DarioGeneral Counsel and SecretarySale4,925$3.84$18.9KForm 4
Feb 18, 2026SMITH J. JEFFERSONChief Research OfficerSale4,925$3.84$18.9KForm 4
Jan 22, 2026Amoroso MichaelPresident and CEOSale34,799$4.17$145.1KForm 4
Jan 21, 2026Scimeca DarioGeneral Counsel and SecretarySale8,854$4.03$35.7KForm 4
Jan 21, 2026Kelly John AlexanderChief Financial OfficerSale15,213$4.03$61.3KForm 4
Jan 21, 2026SMITH J. JEFFERSONChief Research OfficerSale10,200$4.03$41.1KForm 4
Dec 16, 2025Germano Geno JDirectorBuy3,000$4.72$14.2KForm 4
Dec 16, 2025Frankel StanleyDirectorBuy2,700$4.70$12.7KForm 4
Dec 15, 2025Brown MelindaDirectorBuy1,381$4.97$6.9KForm 4
Nov 3, 2025Kelly John AlexanderChief Financial OfficerSale1,303$6.49$8.5KForm 4
Nov 3, 2025Scimeca DarioGeneral Counsel and SecretarySale665$6.49$4.3KForm 4
Nov 3, 2025Amoroso MichaelPresident and CEOSale3,409$6.49$22.1KForm 4
Sep 26, 2025Frankel StanleyDirectorBuy2,700$4.97$13.4KForm 4
Sep 22, 2025Brown MelindaDirectorBuy1,400$4.89$6.8KForm 4
Jul 3, 2025Kelly John AlexanderChief Financial OfficerSale14,827$4.26$63.2KForm 4

All 66 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 94. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Aberdeen Group plc2,230,178$17.5M0.0%No change
Bleichroeder LP2,018,190$15.9M2.8%+355,690
Octagon Capital Advisors LP1,350,000$10.6M1.0%−886,732
Boothbay Fund Management, LLC1,346,004$10.6M0.2%+279,954
BlackRock, Inc.1,172,873$9.2M0.0%+973,112
Vanguard Capital Management LLC1,116,241$8.8M0.0%+205,501
Lynx1 Capital Management LP950,466$7.5M0.9%−34,647
Driehaus Capital Management LLC946,707$7.4M0.0%−48,664
Empery Asset Management, LP776,093$6.1M7.1%−1,192,786
Affinity Asset Advisors, LLC646,576$5.1M0.3%+48,630
Geode Capital Management, LLC620,981$4.9M0.0%+333,891
Mackenzie Financial Corp480,997$3.8M0.0%New
State Street Corp427,325$3.4M0.0%+354,383
ArrowMark Colorado Holdings LLC274,140$2.2M0.1%+95,000
Corient Private Wealth LP245,058$1.9M0.0%+101,206
Two Sigma Investments, LP237,863$1.9M0.0%−69,927
Northern Trust Corp190,188$1.5M0.0%+114,119
Jpmorgan Chase & Co180,452$1.4M0.0%+180,444
Vanguard Fiduciary Trust Co166,538$1.3M0.0%+10,912
Vanguard Portfolio Management LLC161,782$1.3M0.0%New
Goldman Sachs Group Inc139,828$1.1M0.0%+100,076
Squarepoint Ops LLC137,106$1.1M0.0%+93,258
Morgan Stanley130,536$1.0M0.0%+8,259
Commonwealth Equity Services, LLC115,929$911.2K0.0%+3,258
Quarry LP97,915$769.6K0.1%+29,604

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58